ImmunityBio, Inc. IBRX
At closeNov 11, 2026, 7:48 PM EST
After hours · Nov 11, 7:48 PM ET
- YTD
- +236.87%
- 1 year
- +211.68%
Discussion (3500)
Sign in to join the discussion
Thanks
Paul Silberberg your posts are top drawer
Anktiva can and will be used in combination with many therapies.... soon as first line but also as many other therapies fail
Glad I have a long term perspective and have no interest in penny flipping.
$12-$15 in 1 year $25 in 2 years $50-$100 in 5 years
Dr PSS will be on Sean Spicer Friday 🤞 maybe something big will be discussed
"IMMUNITYBIO has gone from a small cap spec
To a mid cap revenue generator"
Cramer agrees and then calls it a spec and of course mentions nothing about the pipeline and clinical trials going on. He is a performer. He has a degree in performing arts and law school at Harvard. So he is an actor and an unethical.......
Watch it my god try using a search engine
At some point quality dividend paying stock will do some catching up. Billions has chased very few stocks. I am sure the pros are already moving away from many and moving to bonds because rates will fall and other forgotten quality stocks.
Why wouldn't Cramer say something like. ImmunityBio is an exciting company with a FDA and good chance more coming and Anktiva seems to have many many future uses. It reminds me of Mercks Keytruda but maybe better. Jim you are fired..... Merck spends billions advertising ImmunityBio spends ZERO. Clean out your desk you are finished.
That's almost an endorsement from the Jim Cramer clown
Cramer is a taking head for MSM propaganda, Wall Street and Big Pharma.
He should explain how a company with a patented treatment and a FDA approval in America and Europe is still a spec. It's an early stage biopharmaceutical company expanding sales and also will be expanding the use of it FDA approved Anktiva with time. He is a POS ass hole.
